Literature DB >> 9285016

Systemic lupus erythematosus: initial manifestations and clinical features after 10 years of disease.

K Y Fong1, J Thumboo, E T Koh, H H Chng, K H Leong, W H Koh, H S Howe, K P Leong, B Lim, D R Koh, S C Ng, P H Feng, M L Boey.   

Abstract

We studied the initial manifestations and late features in our lupus patients. The clinical data of patients fulfilling the American College of Rheumatology criteria for systemic lupus erythematosus (SLE) were entered prospectively for newly diagnosed patients and cumulatively for those with at least 10 years of disease duration. Ninety-seven Group A (newly diagnosed; 86 females and 11 males; mean age 31 years; 83 Chinese, 11 Malays, and 3 Indians) and 58 Group B (more than 10 years disease duration; 56 females and 2 males; mean age 41 years; 50 Chinese, 5 Malays, and 3 Indians) lupus patients were studied. The commonest clinical features in Group A were: haematological (73%), arthritis (57%), malar rash (43%), renal disorder (31%) and photosensitivity (30%). Group B patients had haematological (78%), malar rash (73%), arthritis (69%), renal disorder (59%) and photosensitivity (33%). Renal disorder was significantly increased over the years (P < 0.001). Hypertension was present in 18% (Group A) and 59% (Group B) (P < 0.00001), diabetes mellitus in 5% (Group A) and 10% (Group B) (P = ns), atherosclerosis in 2% (Group A) and 7% (Group B) (P = ns). Cataract formation was not present in Group A patients but was present in 10% of Group B patients. Renal disorders and morbidity factors like hypertension and cataracts increased significantly over the years. Optimum treatment of lupus patients should therefore include close attention to these factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285016

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  3 in total

1.  Increased risk of death in pediatric and adult patients with ESRD secondary to lupus.

Authors:  Sangeeta Sule; Barbara Fivush; Alicia Neu; Susan Furth
Journal:  Pediatr Nephrol       Date:  2010-10-03       Impact factor: 3.714

2.  Risk factors for cataracts in systemic lupus erythematosus (SLE).

Authors:  Khaled Alderaan; Vuk Sekicki; Laurence S Magder; Michelle Petri
Journal:  Rheumatol Int       Date:  2014-09-26       Impact factor: 2.631

Review 3.  Mycophenolate mofetil in the treatment of systemic lupus erythematosus.

Authors:  Ali Sahin
Journal:  Eurasian J Med       Date:  2009-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.